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Abstract
Background: In tumor microenvironment, a continuous cross-talk between cancer cells and other cellular
components is required to sustain tumor progression. Accumulating evidence suggests that exosomes, a
novel way of cell communication, play an important role in such cross-talk. Exosomes could facilitate the
direct intercellular transfer of proteins, lipids, and miRNA/mRNA/DNAs between cells. Since mesenchymal stem
cells (MSCs) can be attracted to tumor sites and become an important component of the tumor microenvironment,
there is an urgent need to reveal the effect of tumor exosomes on MSCs and to further explore the underlying
molecular mechanisms.
Methods: Exosomes were harvested from lung cancer cell line A549 and added to MSCs. Secretion of inflammation-
associated cytokines in exosome-treated MSCs were analyzed by RT-PCR and ELISA. The growth-promoting effect of
exosome-treated MSCs on lung tumor cells was evaluated by in vivo mouse xenograft model. Signaling pathway
involved in exosomes-treated MSCs was detected by PCR array of human toll-like receptor signaling pathway, RT-PCR,
and Western blot.
Results: Data showed that lung tumor cell A549-derived exosomes could induce a pro-inflammatory phenotype
in MSCs named P-MSCs, which have significantly elevated secretion of IL-6, IL-8, and MCP-1. P-MSCs possess a
greatly enhanced ability in promoting lung tumor growth in mouse xenograft model. Analysis of the signaling
pathways in P-MSCs revealed a fast triggering of NF-κB. Genetic ablation of Toll-like receptor 2 (TLR2) by siRNA
and TLR2-neutralizing antibody could block NF-κB activation by exosomes. We further found that Hsp70 present
on the surface of lung tumor exosomes contributed to the induction of P-MSCs by A549 exosomes.
Conclusions: Our studies suggest a novel mechanism by which lung tumor cell-derived exosomes induce pro-
inflammatory activity of MSCs which in turn get tumor supportive characteristics.
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Background
Tumor microenvironment has a close relationship with
tumor development and metastasis [1]. A complex milieu
of non-malignant cells compose tumor microenviron-
ment, contributing to tumor progression by interactions
with tumor cells and/or with each other [2]. Mesen-
chymal stem cells (MSCs) are an important compo-
nent of these cells. MSCs are defined as multipotent
stem cells that have the capacity to give rise to adipo-
cytes, osteoblasts, and chondrocytes [3]. They can be
isolated from a number of tissues including bone
marrow, adipose tissue, and umbilical cord blood. Al-
though the function of naïve MSC in tumor remains
controversial, the tumor-supporting roles of tumor
associated mesenchymal stem cells have been ac-
knowledged [4]. This may be attributed to a long-
time “education” by tumor cells.
* Correspondence: hanqinhanqin@126.com; zhaochunhua@vip.163.com
†Equal contributors
1Center of Excellence in Tissue Engineering, Key Laboratory of Beijing,
Institute of Basic Medical Sciences and School of Basic Medicine, Chinese
Academy of Medical Sciences and Peking Union Medical College, Beijing,
People’s Republic of China
2Center of Translational medicine Peking Union Medical College Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College,
Beijing, People’s Republic of China
© 2016 Li et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Li et al. Journal of Hematology & Oncology  (2016) 9:42 
DOI 10.1186/s13045-016-0269-y
Tumor cells can modulate tumor stromal cells through
intercellular communications. This process can be medi-
ated through direct cell contact or through secreted sig-
naling factors (cytokines, chemokines, and growth
factors) and microvesicles. Exosomes, one kind of mem-
brane vesicles containing proteins, mRNA, miRNAs, and
DNAs, can be produced by tumor cells as well as other
various cell types [5]. Recently, exosomes in tumor
microenvironment are attracting more and more atten-
tion. They are shown to be small particles but big
players in cancer progression and metastasis [6–8] as
cancer cells could reprogram surrounding stromal cells
into tumor supportive myofibroblasts through secreted
exosomes. Data showed that exosomes from ovarian and
breast cancer cells can convert adipose-derived MSCs
(AMSC) into myofibroblast-like cells [9, 10]. Bone-
marrow MSC (BMSC) could also be triggered to differen-
tiate into pro-angiogenic and pro-invasive myofibroblasts
by prostate cancer cell-derived exosomes [11]. Exosomes
released by chronic lymphocytic leukemia cells could in-
duce the transition of stromal cells into cancer-associated
fibroblasts [12].
While most studies concentrate on reprogramming
MSCs into tumor-supportive myofibroblasts by various
cancer cell-derived exosomes, few studies have paid
attention to the immuno-phenotype changes of MSCs
after incubation with tumor cells derived exosomes. Tu-
mors are regarded as chronic injuries that are difficult to
heal [13], and inflammation plays an important role in
tumorigenesis, tumor progression, and metastasis [14].
Besides, MSCs are known for its immunomodulatory cap-
acity through secreting related factors such as cytokines
[15]. Thus, there is an urgent need to dictate the immuno-
phenotype changes of MSCs in tumor microenvironment.
Previous research about MSCs immuno-phenotype
changes often use pre-conditioned MSCs with inflam-
matory factors. Results show that long-term stimulation
with TNF-α, IFN-γ, and other factors could upregulate
the expression of various pro-inflammatory genes in
MSCs [16]. The team of Yufang Shi noticed TNFα-
pretreated BM-MSCs mimicked lymphomas-MSCs in
their chemokine production profile and ability to pro-
mote tumorigenesis of lymphoma, melanoma, and breast
carcinoma [17]. Therefore MSCs that have elevated se-
cretion of inflammatory factors show great relevance
with tumor progression.
In the present study, we will investigate whether exo-
somes from lung tumor cells could affect immuno-
phenotype of AMSCs and try to reveal the molecular
mechanisms involved in this process. Since few studies
have elucidated the mechanisms by which lung cancers
influence AMSC through exosomes and lung cancer is
one of the leading causes of cancer-related death which
incline to transfer to other sites such as bone through
tumor-stromal interactions in late stage [18], it is mean-
ingful to explore this question.
Results
Lung tumor cell A549-derived exosomes are actively
incorporated by MSCs
Exosomes were isolated from serum-free culture medium
of A549 cells through a series of centrifugation and filtra-
tion steps. Under transmission electron microscope, these
exosomes were observed to be cup-shaped vesicles of ap-
proximately 30–120 nm in diameter (Fig. 1a). In addition,
CD63 and HSP70, the protein markers of exosomes, were
also detectable (Fig. 1b). Since exosomes could be labeled
by lipophilic cell tracking dyes, DiO-labeled exosomes
were added to MSCs serum-free culture medium. Exo-
somes uptake was observed 2 h after application (Fig. 1c)
and accumulated over time (data not shown). These data
demonstrate that MSCs can efficiently internalize A549
cell-derived exosomes.
A549 cell-derived exosomes significantly stimulate
inflammatory cytokine production in MSCs
In our previous report about mRNA expression micro-
array [19], we noticed a remarkable elevation of genes
associated with inflammation. Given the important link
between inflammation and cancer progression, we began
to explore whether A549 exosomes could change inflam-
matory response in MSCs. MSCs were exposed to
200 ug/ml A549 exosomes for 24 h, and the cytokine se-
cretion profile of exosome-treated MSCs were detected
by ELISA. Enhanced release of IL-6, IL-8, and MCP-1
was shown (Fig. 2a). To examine whether enhanced
release of cytokines in exosome-treated MSCs was time-
or concentration-dependent; we treated MSCs with dif-
ferent concentrations of A549 exosomes for 24 and 48 h.
As shown in Fig. 2b for cytokine mRNA expression or
Fig. 2c for cytokine protein release, no obvious time- or
concentration-dependent manner was observed. To fur-
ther confirm that the enhanced release of these cytokines
was caused by exosome, we treated MSCs with exosome-
depleted culture medium. As expected, enhanced expres-
sion of IL-6, IL-8, and MCP-1 was not observed (Fig. 2d).
These data suggest that after exposure to cancer cell-
derived exosomes, a new kind of pro-inflammatory MSCs
(P-MSC) was generated.
P-MSCs promote tumor growth in vivo
We next determined whether the altered cytokine ex-
pression in P-MSCs is accompanied by changes in
tumor-promoting capacity in vivo. Using a nude mouse
model, we subcutaneously injected A549 cells with P-
MSCs, MSCs or PBS.As shown in Fig. 3a, the size of tu-
mors significantly increased in the presence of P-MSCs
in respect to tumor alone or tumor co-injected with
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unstimulated MSCs. Such stimulation in tumor growth
was confirmed by measurement of tumor diameter
(Fig. 3b). Since MCP-1-mediated macrophage recruitment
was relevant with tumor growth and angiogenesis [20],
the tumors were excised for examination of immune cell
infiltration. We observed that F4/80 macrophages were
much more abundant in tumors receiving P-MSCs than
those receiving un-stimulated MSCs (Fig. 3c, d). This
tumor-promoting effect and the macrophage-recruiting
function of P-MSCs corresponded well to their high ex-
pression levels of MCP-1 (Fig. 2a), the major macrophage
chemokines. In addition, Ki67 staining also showed ele-
vated cell proliferation rate of A549 cells co-administered
with PMSCs (Fig. 3e, f ). Thus, MSCs educated by A549
exosomes gained an enhanced capacity in recruiting mac-
rophages and in promoting tumor growth in vivo.
NFκB signaling pathway is strikingly activated in P-MSCs
To further investigate the signaling pathways involved in
induction of PMSCs by A549 exosomes, we focused on
TLR pathway as it has been reported to be closely related
to inflammation. We analyzed gene-expression profiles of
MSCs activated by or not by A549 exosomes through the
use of a human toll-like receptor signaling pathway PCR
array (see the Gene list at Table 1). According to the PCR
array analysis (Fig. 4a), inflammation-related pathways in-
cluding NFκB, JNK, and p38 signaling, were actually acti-
vated in P-MSCs. We then investigated the signaling
events triggered by exosomes through Western blotting.
As shown in Fig. 4b, a rapid activation of NFκB was de-
tected by phosphorylation of Ikkα/β and the p65 subunit
that peaked at 0.5–2 h after exosome exposure. Rapid acti-
vation of JNK, ERK, and p38 signaling was not detected
(Fig. 4b). NFκB signaling activation involves phosphoryl-
ation of the p65 protein and translocation of the p65 pro-
tein to the cell nucleus. Therefore, we determined the
localization of p65 in MSCs before and after exposure to
A549 exosomes. As expected, A549 exosome stimulation
resulted in a significant translocation of p65 from a cyto-
plasmic to a nuclear localization in Fig. 4c. Moreover, we
demonstrated that NFκB inhibitor PDTC remarkably sup-
pressed the enhanced expression of IL-6, IL-8, and MCP-
1 induced by A549 exosomes in MSCs (Fig. 4d). Together,
these results suggest that lung tumor-derived exosomes
induce the generation of P-MSCs through activation of
NFκB signaling pathway.
Fig. 1 Characterization of exosomes secreted by A549 cancer cells. a Electron micrograph of exosomes derived from A549 cancer cells.
Scale bar = 200 nm. b Detection of HSP70and CD63 expression in exosomes by Western blot. A549 cells lysate was used as positive
control with loading mass of 20 μg total proteins. Samples represent A549 exosomes. Sample 1 was 1 μg loaded. Sample 2 was 10 μg.
c Internalization of DiO-labled A549 cancer cells derived exosomes at 2 h in MSCs. Scale bar = 100 um
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Exosomes trigger cytokine production in MSCs through
TLR2
The effects of exosomes on NFκB prompted us to study
more closely the role of TLRs in exosome-mediated
signaling. RT-PCR results showed that all TLRs were de-
tectable within 33 cycles in MSCs (Fig. 5a). To deter-
mine which TLR was specifically responsible for tumor
exosome-mediated cytokine up-regulation in MSCs, we
first detected TLRs changes after exosome stimulation.
We found that TLR2, TLR7, and TLR8 mRNA expres-
sion was significantly increased after exosomes stimula-
tion (Fig. 5b). Here, we focused on TLR2 for three
reasons. Firstly, MSCs have higher expression of TLR2
than TLR7 or TLR8 as demonstrated in Fig. 5a, although
up-regulation of TLR7 and TLR8 is more significant
(Fig. 5b). Secondly, TLR2 is localized on cell plasma
membrane whereas TLR7 or TLR8 resides within endo-
somal compartments. Lastly, TLR2 can recognize lipo-
peptides while both TLR7 and TLR8 were shown to
sense single-stranded viral RNA [21–23]. Using a TLR2
neutralizing antibody, we found that blockade of TLR2
in MSCs decreased the expression of inflammatory
factors induced by lung tumor-derived exosomes and
inhibited activation of NFκB signaling pathway (Fig. 5c, d).
Furthermore, we knocked down TLR2 with three pairs
of designed siRNAs, and we chose siRNA3 as it had the
highest interference efficiency of nearly 75 % (Fig. 5e).
SiRNA knockdown of TLR2 also attenuated the ex-
pression of IL-6, IL-8 and MCP-1 (Fig. 5f, Additional file
1). Collectively, these data implicated that TLR2 was
relevant for exosomes-mediated increase of cytokines
IL-6, IL-8, and MCP-1 in MSCs.
Hsp70 on exosomes contribute to cytokine production
through TLR2
To find out whether proteins on exosomes were respon-
sible for PMSCs induction, we treated exosomes with
proteinase K before exposure to MSCs. Interestingly, di-
minished expression of IL-6, IL-8, andMCP-1 could be
observed after treatments with proteinase K (Fig. 6a),
suggesting that proteins on exosomes were related with
MSCs cytokine production. A variety of molecules have
been classified as TLR2 ligands including Versican,
HMGB1, and heat shock proteins (HSP). HSP70 is
Fig. 2 A549 cells derived exosomes significantly stimulate inflammatory cytokines production in MSCs. a Cytokine secretion profile of MSCs and
exosomes-treated MSCs. MSCs were incubated with 200ug/ml exosomes for 24 h. b, c The mRNA level and protein level of IL-6, IL-8, and MCP-1
at different time points across a concentration gradient of exosomes (0, 100, 200, 400 μg/ml). d The mRNA expression changes of IL-6, IL-8 and
MCP-1of MSCs treated with exosomes-depleted A549 cells culture medium (*P < 0.05, **P < 0.01, ***P < 0.001)
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highly expressed on A549 exosomes and it was reported
to be a TLR2 ligand [24]. We then evaluated whether
A549 exosomes induced generation of P-MSCs through
HSP70 or not. Neutralizing antibody of HSP70 could
partially suppress the enhanced expression of IL-6, IL-8,
and MCP-1 induced by A549 exosomes in MSCs
(Fig. 6b). Recombinant human HSP70 (rHSP70) added
to MSCs culture mimicked the effect of A549 exosomes
in a dose-dependent manner (Fig. 6c). Moreover, inter-
fering TLR2 expression with siRNA could attenuate the
effects caused by rHSP70 (Fig. 6d). Altogether, these re-
sults indicate that Hsp70 expressed on the surface of
exosomes could trigger TLR2 signaling in MSCs.
Discussion
Exosomes, first considered as “garbage” released from
cells, are now exerting starring roles in intercellular
communication. Research about exosomes focuses on
three areas: disease biomarker in early stage, membrane
vesicles as conveyors of immune responses, and roles in
cancer [25]. Here, we focus on exosomes in tumor
microenvironment. MSCs can be recruited into tumors
and form a major component of the tumor microenvir-
onment. Emerging evidence show that tumor cells could
modulate MSCs through exosomes including prostate
cancer, melanoma, cancer and so on [26, 27]. Although
many cancer cells could modulate MSCs into myofibro-
blasts, the molecular mechanisms involved are not the
same. One group reported that the tumorigenic repro-
gramming of MSCs in prostate cancer was associated
with exosomal oncogenic factors such as H-ras and K-
ras transcripts, oncomiRNAs, miR-125b etc. [28] An-
other group suggested that prostate cancer cells could
trigger differentiation of fibroblasts into myofibroblasts
through exosomal TGF-β [26]. Breast cancer-derived
exosomes induced the myofibroblastic phenotype and
functionality in AMSCs via the SMAD-mediated signal-
ing pathway [10].
Here, we found that MSCs could be educated by lung
cancer cell-derived exosomes into pro-inflammatory
phenotype and therefore got tumor supportive charac-
teristics. Different from the current research tendency
which focuses on the transition from MSCs to myofibro-
blast caused by tumor cell-derived exosomes, we
emphasize on the inflammation phenotype of MSCs.
Our results were consistent with previous clinical find-
ings that MSCs require pro-inflammatory cytokines to
induce their immunosuppressive function [29, 30]. This
Fig. 3 P-MSCs promote tumor growth in vivo. a Tumor promoting effects of P-MSCs in a xenograft mouse model. PMSC + A549, n = 6. 2 × 106
A549 cells and 2 × 105 exosomes-treated MSCs were injected. MSC + A549, n = 4. 2 × 106 A549 cells and 2 × 105 DF12-treated MSCs were injected.
A549, n = 3, only 2 × 106 A549 cells were injected. b the tumors in each group were dissected and tumor diameters were measured at 2 weeks
after subcutaneous cell injection. c The macrophage infiltration was examined by F4/80 immunohistochemical staining of the tumor tissues harvested
2 weeks after A549 cell inoculation. Representatives of F4/80 staining from each group are shown (magnification 200×). d F4/80 + macrophages were
quantitated and the data represent the mean number of F4/80+ macrophages per 200 × field (three fields per group). e Tumor cell proliferation was
examined by Ki67 immunohistochemical staining of the tumor tissues. Representatives of Ki67 staining from each group are shown (magnification
200×). f Ki67 staining-positive cells were quantified and the data represent the mean number per 200 × field (three fields per group)
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indicates the importance of pro-inflammatory MSCs in
tumors progression.
However, few studies have elucidated mechanisms
about which signal pathways trigger pro-inflammatory
phenotype changes in MSCs. Jerome Paggetti reported
that exosomes released by chronic lymphocytic leukemia
could induce an inflammatory phenotype in stromal cells
through activating AKT, ERK1/2, CREB, and GSK3α/β
signaling pathways [12]. Several related research ex-
plained how tumor cell-derived exosomes cause inflam-
mation in immune cells. Sanchita Bhatnagar et.al found
that exosomes released from bacteria-infected macro-
phages stimulated a pro-inflammatory response in a toll-
like receptor—and myeloid differentiation factor 88
(MyD88)—dependent manner [31]. Fanny Chalmin dem-
onstrated that mice tumor-derived exosomal HSP72 in-
duce IL-6 production by MDSCs through activation of
TLR2 and its adaptor MyD88, leading to Stat3 phosphor-
ylation and the promotion of MDSC immunosuppressive
functions [32]. Some others thought stress-induced Hsp72
activates macrophages, dendritic cells, and neutrophils by
binding to surface bound TLR4 and induce the secretion
of pro-inflammatory cytokines [33]. Alexzander Asea et al.
[34] also illustrated that HSP70 utilized both TLR2 and
TLR4 to transduce its pro-inflammatory signal in a CD14-
dependent fashion.
These studies suggested the involvement of HSP pro-
teins in exosome-associated inflammation. There re-
mains a question—whether pro-inflammatory properties
are unique to cancer-derived exosomes or are an intrin-
sic feature of all exosomes. We hypothesized that exo-
somes have a common determinant, HSP70, which is
one of the inducers of P-MSCs. However, other protein
components of exosomes may also be involved in this
process [35]. These determinants need to be further
characterized.
In our study, we found that HSP70 on the surface of
A549 cell-derived exosomes could activate NF-κB signal-
ing through TLR2 on MSCs. However, TLR2 neutralizing
antibody could partially reduce the effects of exosomes,
suggesting that TLR4, which also can interact with HSP
proteins, may serve as a substitute for TLR2.
Table 1 Gene lists of human toll-like receptor signaling pathway and data for 3D profile
3D profile gene data A B C D E F G H
1 BTK ECSIT IKBKB IRF3 MYD88 RELA TLR3 ACTB
0.64 0.86 0.88 0.84 1.63 1.17 1.39 1.14
2 CASP8 EIF2AK2 IL10 JUN NFKB1 RIPK2 TLR4 B2M
0.86 1.16 0.41 0.75 1.77 1.06 0.74 1.16
3 CCL2 ELK1 IL12A LTA NFKB2 SARM1 TLR5 GAPDH
13.80 0.85 1.35 0.91 0.41 0.81 1.71 0.87
4 CD14 FADD IL1A LY86 NFKBIA SIGIRR TLR6 HPRT1
1.00 0.91 0.60 0.82 3.01 1.19 0.68 1.09
5 CD180 FOS IL1B LY96 NFKBIL1 TAB1 TLR7 RPLPO
2.57 1.18 12.43 1.02 0.27 0.83 7.73 0.79
6 CD80 HMGB1 IL2 MAP2K3 NFRKB TBK1 TLR8
2.57 0.65 0.82 1.10 0.86 0.71 0.55
7 CD86 HRAS IL6 MAP2K4 NR2C2 TICAM1 TLR9
0.82 0.27 21.55 0.95 0.85 1.58 0.71
8 CHUK HSP1A1 IL8 MAP3K1 PELT1 TICAM2 TNF
1.01 1.12 19.37 0.89 1.23 0.75 2.50
9 CLEC4E HSPD1 IRAK1 MAP3K7 PPARA TIRAP TNFRSF1A
0.82 0.82 0.91 0.96 0.79 0.88 1.07
10 CSF2 IFNA1 IRAK2 MAP4K4 PRKRA TLR1 TOLLIP
9.57 0.89 1.79 0.87 1.03 0.48 1.58
11 CSF3 IFNB1 IRAK4 MAPK8 PTGS2 TLR10 TRAF6
43.95 1.42 1.58 0.86 4.75 0.30 0.91
12 CXCL10 IFNG IRF1 MAPK8IP3 REL TLR2 UBE2N
217.01 0.82 2.03 0.74 1.19 5.64 0.94
MSCs were treated with or without 200 μg/ml A549 cell-derived exosomes for 24 h. Total RNA were analyzed using human toll-like receptor signaling pathway
array. Fold change of RNA expression was used for 3D profile (200–24 h/0–24 h)
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Additionally, we should consider the role of RNA
component in exosomes in our future study. We noticed
the decreased expression of inflammatory factors after
pre-treating exosomes with Rnase A (data not shown),
which implied the involvement of exosomal RNAs. It
has been shown that acute stressor exposure modified
plasma exosome-associated Hsp72 and microRNA (miR-
142-5p and miR-203) [36]. Exosomal miRNAs can affect
cells of the tumor microenvironment [37] both in a ca-
nonical (mRNA-targeting) and non-canonical (receptor-
binding) manner. Tumor exosomal miR-21 and miR-29a
can function by binding as ligands to receptors of the
TLR family in immune cells, triggering a TLR-mediated
prometastatic inflammatory response that ultimately
leads to tumor growth and metastasis [38].
Considerable evidence suggests that pro-inflammatory
pathways drive self-renewal of cancer stem-like cells.
HSPs are key players during inflammation besides their
chaperone and cytoprotective functions. Interest in
HSP70 inhibitors is increasing as potential anticancer
agents in recent years [39, 40]. By reprogramming pro-
inflammatory MSCs in tumor microenvironment using
Fig. 4 NFκB signaling pathway is strikingly activated in P-MSCs. a 3D profile of RT2 Profiler™ PCR Array of Human Toll-Like Receptor Signaling
Pathway. b Activation of NF-κB in P-MSC was determined by Western blotting. The fold difference in band intensities was quantified and indicated
under the image using the software of AlphaView. c Representative pictures of cellular immunofluorescence staining for nuclear p65 in
MSCs or P-MSC at 2 h. Immunocytochemistry staining was performed using an anti-p65 antibody (red) and Hoechst (blue) for nuclear
staining. d Relative mRNA expression of IL-6, IL-8, and MCP-1. MSCs were pre-treatment with or without the NF-κB inhibitor (PDTC, 10 μM) at 37 °C for
1 h and then incubated with 200 μg/ml A549 cell-derived exosomes at 37 °C for 24 h (*P < 0.05, **P < 0.01, ***P < 0.001)
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HSP70 inhibitors, tumor progression may be controlled.
But there is still a lot of “dark matter” to reveal before
the welcome of light for cancer patients.
Conclusions
This study demonstrates that lung cancer cell-derived
exosomes could educate naïve MSCs into a new kind of
pro-inflammatory MSCs (P-MSCs) by activating TLR2/
NF-κB signaling through exosomal surface HSP70. Im-




Exosome extraction was performed as previously de-
scribed [41]. Briefly, A549 cells were cultured in serum-
free DF12 medium for 24 h. Then, the culture medium
was collected and centrifuged at 800g for 5 min and
additional 2000g for 10 min to remove lifted cells.
The supernatant was subjected to filtration on a 0.1-mm-
pore polyethersulfone membrane filter (Corning) to
remove cell debris and large vesicles, followed by concen-
tration by a 100,000 Mw cutoff membrane (CentriPlus-70,
Millipore). The volume of supernatant was reduced from
Fig. 5 Exosomes trigger cytokine production in MSCs through TLR2. a The expression level of TLR 1 ~ 10 of MSCs. GAPDH was used as control.
b mRNA expression changes of TLR2, 7, 8 were detected by RT-PCR after treatment with exosomes. c mRNA expression changes of IL-6, IL-8, and
MCP-1 of MSCs. MSCs were pre-treated withTLR2 neutralizing antibody or mouse IgG2b isotype control at 37 °C for 1 h and then incubated with
exosomes for 24 h. d Western blotting analysis of NF-κB activation in P-MSCs. MSCs treated with mouse IgG2b isotype control was used as control.
e The interfering efficiency of three pairs of TLR2 siRNAs was measured by RT-PCR. f mRNA expression changes of IL-6, IL-8, and MCP-1. MSCs were
stimulated with exosomes after knockdown of TLR2 by siRNA for 24 h (*P < 0.05, **P < 0.01, ***P < 0.001)
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approximately 250–500 mL to less than 5 mL. The
supernatant was then ultracentrifuged at 100,000g for
1 h at 4 °C using 70Ti rotor (Beckman Coulter). The
resulting pellets were resuspended in 6 mL PBS and
ultracentrifuged at 100,000 g for 1 h at 4 °C using
100Ti rotor (Beckman Coulter).
Transmission electron microscopy
Purified exosomes were fixed with 1 % glutaraldehyde in
PBS (pH 7.4). After rinsing, a 20-uL drop of the suspen-
sion was loaded onto a formvar/carbon-coated grid,
negatively stained with 3 % (w/v) aqueous phosphotung-
stic acid for 1 min, and observed by transmission elec-
tron microscope.
Isolation and culture of MSCs from adipose tissue
Human adipose tissue was obtained from liposuction as-
pirates with informed consent of the donors and was
performed according to procedures provided by the
Ethics Committee at the Chinese Academy of Medical
Sciences and Peking Union Medical College. The isola-
tion and culture procedures were described as previously
reported [42]. hAMSCs were resuspended in 12 ml cul-
ture medium and seeded at a density of 2 × 106 cells in a
75-cm2 culture flask. Cell cultures were maintained at
37 °C in a humidified incubator with 5 % CO2 and pas-
saged with trypsin/EDTA when cells were confluent.
Passage 3 cells were used for following experiments.
Quantitative real-time polymerase chain reaction
Cultured cells were lysed by TRIzol (Invitrogen, USA),
and RNA was extracted according to the manufacturer’s
instruction. One microgram of total RNA from each sam-
ple was reverse transcribed using M-MLV (Takara) in a
final volume of 20 uL. The polymerase chain reaction
(PCR) amplification was carried out using the Step-one
System (Bio-Rad) with SYBR Green Mastermix (Takara).
All quantitative real-time PCR (qRT-PCR) results were
carried out in duplicate and normalized to GAPDH. The
primer of the related gene list is found in Table 2.
Western blotting
After washing twice with cold PBS, cells were lysed in
RIPA lysis buffer (Beyotime, Shanghai, China) with
Fig. 6 Hsp70 on exosomes contribute to cytokine production through TLR2. a mRNA expression changes of IL-6, IL-8, and MCP-1. Exosomes were
pre-treated with proteinase K (5 μg/ml) at 37 °C for 1 h and then treated at 95 °C for 10 min after proteinase K treatment to abolish its activity.
Proteinase K treatment alone was used as another control. b mRNA expression changes of IL-6, IL-8, and MCP-1. Exosomes were pre-treated with
or without anti-HSP70 antibody at 37 °C for 1 h. 10 μg/ml anti-HSP70 was used for blocking. c mRNA expression changes of IL-6,IL-8, and MCP-1
in MSCs treated with different concentrations of rHSP70 proteins for 24 h. d mRNA expression changes of IL-6, IL-8, and MCP-1 in MSCs treated
with rhHSP70 after knockdown of TLR2 by siRNA for 24 h (*P < 0.05, **P < 0.01, ***P < 0.001)
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1 mM PMSF and protease inhibitor cocktail on ice for
30 min, manually scraped from culture plates and then
quantified using the BCA Protein Assay Kit (Beyotime).
Proteins were separated on 10 % sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) gels,
electroblotted onto a polyvinylidene difluoride (PVDF)
membrane (0.22 μm, Millipore, Billerica, MA, USA). The
membranes were blocked with 5 % BSA and incubated
with specific antibodies overnight at 4 °C and then were
incubated with horseradish peroxidase (HRP)-conjugated
secondary antibody for 1 h at room temperature. The pri-
mary antibodies were as follows: IKKα/β, phosphorus
IKKα/β, p65, phosphorus p65, JNK, phosphorus JNK,
phosphorus p38 (1/1000, Cell Signaling Technology,
USA), CD63, HSP70 (1/1000, Abcam), GAPDH (1/1000,
Santa cruz), and β-actin (1/1000, Zhongshan, Beijing
China). Secondary (HRP)-conjugated antibodies were
purchased from NeoBioscience. Antibody and antigen
complexes were detected using chemiluminescent ECL
reagent (Millipore, USA).
siRNA transfection
Three pairs of siRNA of TLR2 were designed and syn-
thesized (Gene Pharma, Inc., Shanghai, China). The
synthetics were transfected into AMSCs at the final con-
centration of 200 nM using lipofectamine 2000
(Invitrogen, USA) according to the manufacturer’s in-
structions. The whole transfection process was proceeded
in a non-serum medium named opti-mem (Gibco, USA)
for 6 h at 37 °C in a humidified environment containing
5 % CO2. After transfection, the medium was changed
into DF12 medium with or without cancer exosomes.
Cytokine analysis
Culture supernatants were collected after treatment with
or without exosomes for 24 h. The concentrations of all
cell cytokines in supernatants were measured using
ELISA kits (BD Technologies).
Immunofluorescence staining
The cultured cells were fixed at 4 °C in ice-cold metha-
nol for 10 min, washed three times in phosphate-
buffered saline (PBS), and then permeabilized in 0.1 %
Triton X-100/PBS for 10 min at room temperature.
Nonspecific binding was blocked with 0.5 % Tween-20/
PBS containing 1 % bovine serum albumin (BSA) for
30 min. The primary antibodies were incubated at 4 °C
overnight. The secondary antibodies incubated for 1 h at
Fig. 7 A schematic illustration showed that lung tumor cell-derived exosomes could educate naïve MSCs into a new kind of pro-inflammatory
MSCs (P-MSCs) by activating TLR2/NF-κB signaling through exosomal surface HSP70
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room temperature. The incubated cells were washed in
PBS, and Hoechst 33342 (Sigma-Aldrich) was used to
visualize nuclei. p65 antibody (10745-1-AP) was pur-
chased from Proteintech.
Animal experiments
All nude mice were purchased from the Laboratory Ani-
mal Center of the Chinese Academy of Medical Sciences
(Beijing, China). All mice were bred and maintained
under specific pathogen-free conditions. Animal use and
experimental procedures were approved by the Animal
Care and Use Committee of the Chinese Academy of
Medical Sciences. All nude mice received a subcutane-
ous injection of 2 × 106 A549 cells. One group received a
subcutaneous injection of 2 × 105 PMSCs. The other
group received a subcutaneous injection of 2 × 105
MSCs. The last group only received an injection of A549
cells. The tumor volume was measured after 2 weeks.
The tumor tissues were fixed with 10 % PFA and the
peripheral blood were collected for C-flow analysis. Each
group was treated with HE, Ki67, and F4/80 staining.
Ki67 antibody was purchased from Proteintech (19972-
1-AP). F4/80 antibody was purchased from Abcam
(ab6640).
Statistical analysis
Data are presented as mean ± SD. Comparisons between
groups were analyzed via Student’s t test. Differences
were considered statistically significant at *P < 0.05,
**P < 0.01, and ***P < 0.001.
Additional file
Additional file 1: mRNA expression changes of IL-6, IL-8 and MCP-1
in MSCs stimulated with exosomes after knockdown of TLR2 by siRNA
combinations for 24h. (TIF 236 kb)
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